Skip to main content
. Author manuscript; available in PMC: 2012 Feb 2.
Published in final edited form as: Crit Rev Eukaryot Gene Expr. 2002;12(3):175–191. doi: 10.1615/critreveukaryotgeneexpr.v12.i3.20

TABLE 2.

A List of Tumors Susceptible to Endostatin’s Action In Vivo

Tumor Source of endostatin Dose Reference
786-0 renal clear cell Murine soluble yeast 10 mg/kg/day (Dhanabal et al., 1999a)
RC-9, renal cell carcinoma Human soluble mammalian 10–250 µg/kg/day (Yamaguchi et al., 1999)
MDA-MB-435 breast orthotopic Liposome-murine 2.9 µg of plasmid/mouse (Chen et al., 1999)
B16BL6 melanoma Human soluble yeast 1.5 mg/kg/day (Sim et al., 1999)
MA148 ovarian carcinoma Murine soluble yeast 20 mg/kg/day + angiostatin same dose (Yokoyama et al., 2000a)
MC38 adenocarcinoma Adenovirus murine endostatin gene 1 × 109 pfu (Feldman et al., 2000a)
DMBA induced primary Rat insoluble endostatin 20 mg/kg/day (Perletti et al., 2000)
BT4C glioma Alginate-encapsulated endostatin 0.2 µg/mL per capsule (Read et al., 2001b)
U-87MG glioma Alginate-encapsulated human endostatin 150.8 ng/mL (Joki et al., 2001)